Bio2Business Featured Speaker Series

SHAREemail the linkcopy link to Clipboard
The Importance of Understanding the Solid Form Landscape of an API During Early Product Development.
19 June: 15:00 - 15:15
Mr Jonathan Loughrey, Head of Screening Services, Cambrex
ABSTRACT
During development, understanding the polymorphic landscape of an active pharmaceutical ingredient (API) is of utmost importance to ensure that the most stable form is reproducibly prepared and no batch-to-batch variability in solubility, dissolution rate, stability, crystallinity, or particle size is encountered. Water plays a key part in understanding the polymorphism of an API due to its presence in excipients, the atmosphere, or mode of administration. Within a product, water can prompt dissolution of soluble components, increase interactions between API and excipients, or induce API-specific phase transitions. Due to these risks, the impact of water should be fully understood in all aspects of drug development and manufacturing. Cambrex Edinburgh will present methods to locate and understand hydrated forms and describe the impact they have on downstream processing.

BIOGRAPHY
Dr Jonathan Loughrey, Head of Screening Services, is based in Edinburgh and oversees the Solid Form Screening group who provide high quality polymorph, salt, co-crystal, and early crystallisation screening studies for a global client base. Jonathan’s career started at Abbott Life Sciences (The Netherlands) where he was a process solid form specialist. After obtaining a Ph.D. in Chemistry (University of Leeds) and numerous postdoctoral positions within the UK and USA, he joined Solid Form Solutions (now Cambrex) as a crystallisation scientist to develop scaleable process crystallisations for small molecules and peptides. Over the past five years, Jonathan has moved to oversee the Solid Form Screening group and now provides clear advice on solid form control for a given API during drug substance and drug product development

COMPANY PROFILE
Cambrex
Cambrex is the small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. Enjoy working with our experts to accelerate your small molecule therapeutics into the market.
With over 35 years’ experience and a growing team of over 2,000 experts servicing global clients from sites in North America and Europe, Cambrex is tried and trusted in branded and generic markets for API and dosage form development and manufacturing.

Cambrex offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and highly potent APIs. In addition, Cambrex can support conventional dosage forms including oral solids, semi-solids and liquids and has the expertise to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.

Our locations
Cambrex has a presence in thirteen locations globally, including a corporate headquarters in East Rutherford, NJ, USA.

Our North American facilities are located in Whippany, NJ, Charles City, IA, High Point and Durham, NC, Longmont, CO and Agawam, MA in the USA and Mirabel, Québec in Canada.
Our European facilities are located in Karlskoga, Sweden, Edinburgh, Scotland, Paullo, Milan in Italy, Tallinn, Estonia and Wiesbaden, Germany.

Regardless of location, our team of experts have a shared goal to use our technologies and expertise to accelerate your small molecule therapeutics into the market.

Learn more about BOS2019
BOS Testimonials|2018                      BOS Testimonials|2019